Abstract
Purpose: Selenium is frequently in nutraceuticals for pregnancy, given its role on fertility and thyroid metabolism. However, most evidence rise from non-controlled studies. We aimed to evaluate the protective effect of selenium against thyroid autoimmunity during and after pregnancy. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed and promoted by the Young Italian Endocrinologists Group (EnGioI)—Italian Society of Endocrinology. Forty-five women with thyroiditis in pregnancy were enrolled and randomly assigned to L-selenomethionine (L-Se-Met) 83 mcg/day or placebo (PLB) and evaluated at 10 ± 2 (T1), 36 ± 2 weeks of gestation (T2) and 6 months after delivery (postpartum, PP). Results: We measured a significant reduction of autoantibodies after pregnancy in L-Se-Met group [at PP: TgAb 19.86 (11.59–52.60), p < 0.01; TPOAb 255.00 (79.00–292.00), p < 0.01], and an antibodies titer’s rebound in PLB group (TgAb 151.03 ± 182.9, p < 0.01; TPOAb 441.28 ± 512.18, p < 0.01). A significant increase in selenemia was measured in L-Se-Met group at T2 (91.33 ± 25.49; p < 0.01) and PP (93.55 ± 23.53; p = 0.02). Two miscarriage occurred in PLB. No differences were found in thyroid volume, echogenicity, quality of life, maternal/fetal complications. Conclusions: SERENA study demonstrated a beneficial effect of L-Se-Met supplementation on autoantibody titer during pregnancy and on postpartum thyroiditis recurrence.
| Original language | English |
|---|---|
| Pages (from-to) | 542-550 |
| Journal | Endocrine |
| Volume | 66 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Autoimmune thyroiditis
- Fetal risk
- L-selenomethionine
- Maternal complications
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Selenium supplementation in the management of thyroid autoimmunity during pregnancy : results of the “SERENA study”, a randomized, double-blind, placebo-controlled trial. / Mantovani, G.; Isidori, A. M.; Moretti, C.; Di Dato, C.; Greco, E.; Ciolli, P.; Bonomi, M.; Petrone, L.; Fumarola, A.; Campagna, G.; Vannucchi, G.; Di Sante, S.; Pozza, C.; Faggiano, A.; Lenzi, A.; Giannetta, E.
In: Endocrine, Vol. 66, No. 3, 01.01.2019, p. 542-550.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Selenium supplementation in the management of thyroid autoimmunity during pregnancy
T2 - results of the “SERENA study”, a randomized, double-blind, placebo-controlled trial
AU - Mantovani, G.
AU - Isidori, A. M.
AU - Moretti, C.
AU - Di Dato, C.
AU - Greco, E.
AU - Ciolli, P.
AU - Bonomi, M.
AU - Petrone, L.
AU - Fumarola, A.
AU - Campagna, G.
AU - Vannucchi, G.
AU - Di Sante, S.
AU - Pozza, C.
AU - Faggiano, A.
AU - Lenzi, A.
AU - Giannetta, E.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Purpose: Selenium is frequently in nutraceuticals for pregnancy, given its role on fertility and thyroid metabolism. However, most evidence rise from non-controlled studies. We aimed to evaluate the protective effect of selenium against thyroid autoimmunity during and after pregnancy. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed and promoted by the Young Italian Endocrinologists Group (EnGioI)—Italian Society of Endocrinology. Forty-five women with thyroiditis in pregnancy were enrolled and randomly assigned to L-selenomethionine (L-Se-Met) 83 mcg/day or placebo (PLB) and evaluated at 10 ± 2 (T1), 36 ± 2 weeks of gestation (T2) and 6 months after delivery (postpartum, PP). Results: We measured a significant reduction of autoantibodies after pregnancy in L-Se-Met group [at PP: TgAb 19.86 (11.59–52.60), p < 0.01; TPOAb 255.00 (79.00–292.00), p < 0.01], and an antibodies titer’s rebound in PLB group (TgAb 151.03 ± 182.9, p < 0.01; TPOAb 441.28 ± 512.18, p < 0.01). A significant increase in selenemia was measured in L-Se-Met group at T2 (91.33 ± 25.49; p < 0.01) and PP (93.55 ± 23.53; p = 0.02). Two miscarriage occurred in PLB. No differences were found in thyroid volume, echogenicity, quality of life, maternal/fetal complications. Conclusions: SERENA study demonstrated a beneficial effect of L-Se-Met supplementation on autoantibody titer during pregnancy and on postpartum thyroiditis recurrence.
AB - Purpose: Selenium is frequently in nutraceuticals for pregnancy, given its role on fertility and thyroid metabolism. However, most evidence rise from non-controlled studies. We aimed to evaluate the protective effect of selenium against thyroid autoimmunity during and after pregnancy. Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed and promoted by the Young Italian Endocrinologists Group (EnGioI)—Italian Society of Endocrinology. Forty-five women with thyroiditis in pregnancy were enrolled and randomly assigned to L-selenomethionine (L-Se-Met) 83 mcg/day or placebo (PLB) and evaluated at 10 ± 2 (T1), 36 ± 2 weeks of gestation (T2) and 6 months after delivery (postpartum, PP). Results: We measured a significant reduction of autoantibodies after pregnancy in L-Se-Met group [at PP: TgAb 19.86 (11.59–52.60), p < 0.01; TPOAb 255.00 (79.00–292.00), p < 0.01], and an antibodies titer’s rebound in PLB group (TgAb 151.03 ± 182.9, p < 0.01; TPOAb 441.28 ± 512.18, p < 0.01). A significant increase in selenemia was measured in L-Se-Met group at T2 (91.33 ± 25.49; p < 0.01) and PP (93.55 ± 23.53; p = 0.02). Two miscarriage occurred in PLB. No differences were found in thyroid volume, echogenicity, quality of life, maternal/fetal complications. Conclusions: SERENA study demonstrated a beneficial effect of L-Se-Met supplementation on autoantibody titer during pregnancy and on postpartum thyroiditis recurrence.
KW - Autoimmune thyroiditis
KW - Fetal risk
KW - L-selenomethionine
KW - Maternal complications
UR - http://www.scopus.com/inward/record.url?scp=85067687869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067687869&partnerID=8YFLogxK
U2 - 10.1007/s12020-019-01958-1
DO - 10.1007/s12020-019-01958-1
M3 - Article
C2 - 31129812
AN - SCOPUS:85067687869
VL - 66
SP - 542
EP - 550
JO - Endocrine
JF - Endocrine
SN - 1355-008X
IS - 3
ER -